Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.94 |
| ▸ | CSF1R | P07333 | 3/20 | 0.94 |
| ▸ | PIM1 | P11309 | 3/20 | 0.94 |
| ▸ | CLK2 | P49760 | 3/20 | 0.94 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.94 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.94 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.94 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.94 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.94 |
| ▸ | INSR | P06213 | 2/20 | 0.75 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.75 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.75 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.75 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.75 |
| ▸ | MELK | Q14680 | 1/20 | 0.75 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31108085 | 1.00 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL526635 | 1.00 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL29770510 | 1.00 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4971450 | 1.00 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL29583127 | 1.00 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4970460 | 0.97 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4970621 | 0.97 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4970722 | 0.97 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4974096 | 0.89 | PARP1 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4971245 | 0.86 | MAP4K4 (1.00) | PARP1PARP2MAP4K4CSF1RPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957477-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2008-08-20 | — | — | EP | claimed |
| US-20070179136-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-08-02 | — | — | US | claimed |
| WO-2007041357-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-04-12 | — | — | WO | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2026043376-A1 | TRANS-CYCLOOCTENE FORMULATIONS | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2026-02-26 | — | — | WO | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-8697736-B2 | 1H-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent PARP inhibitors | ABBVIE INC. (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2598491-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | Cadila Healthcare Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137695-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012038751-A3 | PROCESS FOR THE PURIFICATION OF AROMATIC DICARBOXYLIC ACID | DAVY PROCESS TECHNOLOGY LIMITED (GB) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012014221-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| EP-1957477-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-1957477-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070179136-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| WO-2007041357-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | PARP1 2146/4885PARP2 1679/4885MAP4K4 4447/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | PARP1 3731/4885PARP2 2943/4885MAP4K4 4024/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | PARP1 3986/4885PARP2 4012/4885MAP4K4 3987/4885 |
| US-20130137695-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885MAP4K4 855/4885 |
| US-20070179136-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885MAP4K4 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.